<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />


<meta name="author" content="Serdar Turkarslan" />


<title>Patient Analysis Pipeline</title>

<script src="site_libs/header-attrs-2.7/header-attrs.js"></script>
<script src="site_libs/jquery-1.11.3/jquery.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<link href="site_libs/highlightjs-9.12.0/textmate.css" rel="stylesheet" />
<script src="site_libs/highlightjs-9.12.0/highlight.js"></script>

<link rel="icon" href="https://github.com/workflowr/workflowr-assets/raw/master/img/reproducible.png">
<!-- Add a small amount of space between sections. -->
<style type="text/css">
div.section {
  padding-top: 12px;
}
</style>



<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>





<link rel="stylesheet" href="style.css" type="text/css" />



<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark it active
  menuAnchor.tab('show');

  // if it's got a parent navbar menu mark it active as well
  menuAnchor.closest('li.dropdown').addClass('active');

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "&#xe258;";
  border: none;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-default  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">SYGNOMICS Patient Report</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li>
  <a href="index.html">Summary</a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-expanded="false">
    P76156 2020
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="P76156_3_Analysis.html">P76156 2020 Network</a>
    </li>
    <li>
      <a href="P76156_3_Mutation_Analysis.html">P76156 2020 Mutations</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-expanded="false">
    P76156 2021
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="P76156_6_Analysis.html">P76156 2021 Network</a>
    </li>
    <li>
      <a href="P76156_6_Mutation_Analysis.html">P76156 2021 Mutations</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">Patient Analysis Pipeline</h1>
<h4 class="author">Serdar Turkarslan</h4>
<h4 class="date">1/19/2022</h4>

</div>


<pre><code>
── Column specification ────────────────────────────────────────────────────────
cols(
  .default = col_character(),
  `Drug Constrained Regulon Activity` = col_double(),
  `Drug Constrained Program Activity` = col_double(),
  `All Regulon(s)` = col_number(),
  `Overactive Regulon(s)` = col_number(),
  `Underactive Regulon(s)` = col_double(),
  `Underactive Program(s)` = col_double(),
  max_glioblastoma.multiforme_phase = col_double(),
  `Other FDA Appr.` = col_logical(),
  TargetMutatedInPatient = col_logical(),
  MutatedInPatient = col_logical(),
  MutatedDetail = col_logical()
)
ℹ Use `spec()` for the full column specifications.</code></pre>
<pre><code>
── Column specification ────────────────────────────────────────────────────────
cols(
  .default = col_logical(),
  Patient_ID = col_character(),
  D_PFS = col_double(),
  D_PFS_FLAG = col_double(),
  Subtype = col_character(),
  MGMT_Status = col_character(),
  Histological_type = col_character(),
  kmEstimate = col_double(),
  GuanScore = col_double(),
  Classer = col_character(),
  Classer_binary = col_double(),
  GuanScoreZScored = col_double(),
  Risk_predicted = col_character(),
  RiskClassAutophagy = col_character(),
  RiskClassAutophagy_binary = col_double(),
  X172 = col_character()
)
ℹ Use `spec()` for the full column specifications.</code></pre>
<div id="target-vegfa" class="section level1">
<h1>1. Target: <a name=VEGFA href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=VEGFA">VEGFA</a></h1>
<button type="button" class="btn btn-info">
Drugs <span class="badge badge-light"> 4 </span>
</button>
<button type="button" class="btn btn-primary">
Active Regulons <span class="badge badge-light"> 21 </span>
</button>
<button type="button" class="btn btn-primary">
Regulon Activity <span class="badge badge-light"> 0.913 </span>
</button>
<button type="button" class="btn btn-primary">
Hallmarks <span class="badge badge-light"> 3 </span>
</button>
<button type="button" class="btn btn-primary disabled">
Mutated in patient <span class="badge badge-light"> No </span>
</button>
<div id="drugs" class="section level3">
<h3>Drugs</h3>
<div id="htmlwidget-7c9bc05e69bc1b95f864" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-7c9bc05e69bc1b95f864">{"x":{"filter":"none","vertical":false,"data":[["1","2","3","4"],["<a name=#BEVACIZUMAB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=BEVACIZUMAB\">BEVACIZUMAB<\/a>","<a name=#PEGAPTANIB SODIUM href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=PEGAPTANIB SODIUM\">PEGAPTANIB SODIUM<\/a>","<a name=#RANIBIZUMAB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=RANIBIZUMAB\">RANIBIZUMAB<\/a>","<a name=#BROLUCIZUMAB href=\"https://www.ebi.ac.uk/chembl/g/#search_results/all/query=BROLUCIZUMAB\">BROLUCIZUMAB<\/a>"],["INHIBITOR","ANTAGONIST","INHIBITOR","INHIBITOR"],[null,null,null,null],[4,0,0,0],["TRUE","TRUE","TRUE","TRUE"],["<a href=\"https://beta.clinicaltrials.gov/search?patient=BEVACIZUMAB AND  Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=PEGAPTANIB SODIUM AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=RANIBIZUMAB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>","<a href=\"https://beta.clinicaltrials.gov/search?patient=BROLUCIZUMAB AND Glioblastoma&locStr=&distance=0\"> <button type=\"button\" class=\"btn btn-primary btn-sm disabled\">Clinical Trials<\/button><\/a>"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Drug<\/th>\n      <th>Drug Action<\/th>\n      <th>Toxicity Class<\/th>\n      <th>Max GBM Phase<\/th>\n      <th>FDA Approved<\/th>\n      <th>Clinical Trials<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":4},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false,"rowCallback":"function(row, data, displayNum, displayIndex, dataIndex) {\nvar value=data[5]; $(this.api().cell(row, 5).node()).css({'color':value == \"TRUE\" ? \"green\" : value == \"FALSE\" ? \"gray\" : null});\n}"}},"evals":["options.rowCallback"],"jsHooks":[]}</script>
</div>
<div id="model-evidence" class="section level3">
<h3>Model Evidence</h3>
<p><strong>21</strong> regulons containing the target(s), <strong>VEGFA</strong> are overactive in this patient.</p>
</div>
<div id="hallmarks-enrichment" class="section level3">
<h3>Hallmarks Enrichment</h3>
<p><a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_HYPOXIA">HALLMARK_HYPOXIA</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_MTORC1_SIGNALING">HALLMARK_MTORC1_SIGNALING</a> <a href="https://www.gsea-msigdb.org/gsea/msigdb/cards/HALLMARK_TNFA_SIGNALING_VIA_NFKB">HALLMARK_TNFA_SIGNALING_VIA_NFKB</a></p>
</div>
<div id="literature-evidence" class="section level3">
<h3>Literature Evidence</h3>
<div id="htmlwidget-e3cddfd3e29fdc7b18a6" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-e3cddfd3e29fdc7b18a6">{"x":{"filter":"none","vertical":false,"data":[["1"],["VEGFA"],["bevacizumab has been shown to be effective in combination with irinotecan for recurrent high grade glioma with a radiographic response noted in around 60% of patients, and a 6-month overall survival of 77% in patients treated with this regimen 10, 11. Other phase II trials have shown and confirmed that bevacizumab as a single agent or in combination with irinotecan are active and tolerable in patients with recurrent glioblastoma 12, 13."],["GBM"],["<a href=\"https://pubmed.ncbi.nlm.nih.gov/26284131\">The Prognostic Significance of Combining VEGFA, FLT1 and KDR mRNA Expressions in Brain Tumors<\/a>"],["26284131"],[2015],["Publication"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Gene<\/th>\n      <th>Evidence<\/th>\n      <th>Disease<\/th>\n      <th>Title<\/th>\n      <th>PMID<\/th>\n      <th>Year<\/th>\n      <th>Type<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"","columnDefs":[{"className":"dt-right","targets":6},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="glioblastoma-clinical-trials" class="section level3">
<h3>Glioblastoma Clinical Trials</h3>
<div id="htmlwidget-22088ffde22082819000" style="width:100%;height:100%;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-22088ffde22082819000">{"x":{"filter":"none","vertical":false,"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63","64","65","66","67","68","69","70","71","72","73","74","75","76","77","78","79","80","81","82","83","84","85","86","87","88","89","90","91","92","93","94","95","96","97","98","99","100","101","102","103","104","105","106","107","108","109","110","111","112","113","114","115","116","117","118","119","120","121","122","123","124","125","126","127","128","129","130","131","132","133"],["NCT03661723","NCT02076152","NCT04952571","NCT02511405","NCT04121455","NCT02841332","NCT01102595","NCT03743662","NCT02157103","NCT04421378","NCT03149003","NCT01209442","NCT02336165","NCT01782976","NCT03631836","NCT01290263","NCT02669173","NCT02342379","NCT00817284","NCT02047214","NCT00762255","NCT01443676","NCT01933815","NCT02120287","NCT00345163","NCT01349660","NCT02974621","NCT02285959","NCT01632228","NCT01860638","NCT00892177","NCT01564914","NCT01474239","NCT01435395","NCT02017717","NCT00943826","NCT01308684","NCT01115491","NCT00800917","NCT01091792","NCT00984438","NCT03573986","NCT00590681","NCT02078648","NCT00904852","NCT01788280","NCT04406272","NCT01266031","NCT02768389","NCT05118776","NCT02898012","NCT01260506","NCT02754362","NCT03463265","NCT01149850","NCT01903330","NCT01067469","NCT00525525","NCT03452579","NCT02337491","NCT01331616","NCT00883298","NCT00805961","NCT02761070","NCT00967330","NCT00884741","NCT01086345","NCT02743078","NCT02663271","NCT01814813","NCT01730950","NCT01894061","NCT01004874","NCT00921167","NCT04074785","NCT01811498","NCT00433381","NCT02060955","NCT02698280","NCT02010606","NCT01836536","NCT01386710","NCT02348255","NCT01269853","NCT01498328","NCT00968240","NCT02386826","NCT02414165","NCT04681677","NCT00463073","NCT00501891","NCT01290939","NCT03890952","NCT00586508","NCT00906516","NCT00621686","NCT02343549","NCT00720356","NCT01013285","NCT00612430","NCT01648348","NCT02833701","NCT03532295","NCT00939991","NCT02142803","NCT03607643","NCT00671970","NCT01582152","NCT04446416","NCT01609790","NCT01967810","NCT01738646","NCT01441388","NCT01740258","NCT02052648","NCT01478321","NCT00667394","NCT00458731","NCT01189240","NCT01999270","NCT01339039","NCT01837862","NCT01392209","NCT01884740","NCT00879437","NCT01743950","NCT00337207","NCT00268359","NCT00795665","NCT01164189","NCT00352521","NCT01183663","NCT00782756"],["<a href=\"https://ClinicalTrials.gov/show/NCT03661723\">Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02076152\">FMISO PET Study of Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT04952571\">Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients With Recurrent Glioblastoma (GBM)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02511405\">A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT04121455\">Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02841332\">Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01102595\">Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03743662\">Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02157103\">A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT04421378\">A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03149003\">A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01209442\">Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02336165\">Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01782976\">Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03631836\">Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01290263\">Amgen 386 for Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02669173\">Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02342379\">TH-302 in Combination With Bevacizumab for Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00817284\">Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02047214\">Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00762255\">A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01443676\">Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01933815\">Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02120287\">Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00345163\">A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01349660\">Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02974621\">Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02285959\">Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01632228\">A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01860638\">A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00892177\">Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01564914\">A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01474239\">A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01435395\">Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02017717\">A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00943826\">A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01308684\">A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01115491\">A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00800917\">A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01091792\">Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00984438\">Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03573986\">Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00590681\">Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02078648\">Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00904852\">Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01788280\">Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT04406272\">VB-111 in Surgically Accessible Recurrent/Progressive GBM<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01266031\">Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02768389\">Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT05118776\">Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02898012\">Temozolomide Plus Bevacizumab in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01260506\">Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02754362\">A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03463265\">ABI-009 (Nab-rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01149850\">Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01903330\">ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01067469\">Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00525525\">Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03452579\">Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02337491\">Pembrolizumab +/- Bevacizumab for Recurrent GBM<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01331616\">Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00883298\">Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00805961\">RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02761070\">Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00967330\">A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00884741\">Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01086345\">Radiosurgery Plus Bevacizumab in Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02743078\">Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02663271\">TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01814813\">Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01730950\">Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01894061\">NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01004874\">Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00921167\">A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT04074785\">Pilot Study of Abemaciclib With Bevacizumab in Recurrent Glioblastoma Patients With Loss of CDKN2A/B or Gain or Amplification of CDK4/6<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01811498\">Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00433381\">Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02060955\">Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02698280\">Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02010606\">Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01836536\">Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01386710\">Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02348255\">NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01269853\">Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01498328\">A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00968240\">Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02386826\">INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02414165\">The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT04681677\">Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00463073\">Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00501891\">Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01290939\">Bevacizumab and Lomustine for Recurrent GBM<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03890952\">Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00586508\">Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00906516\">Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00621686\">Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02343549\">A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00720356\">Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01013285\">Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00612430\">Ph II Bevacizumab + Etoposide for Pts w Recurrent MG<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01648348\">Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02833701\">Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03532295\">INCMGA00012 and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00939991\">Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02142803\">TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT03607643\">A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00671970\">Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01582152\">Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT04446416\">Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01609790\">Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01967810\">ANG1005 in Patients With Recurrent High-Grade Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01738646\">Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01441388\">A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01740258\">Bevacizumab Beyond Progression (BBP)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT02052648\">Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01478321\">Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00667394\">Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00458731\">Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01189240\">RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01999270\">Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01339039\">Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01837862\">A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01392209\">Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01884740\">Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00879437\">Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01743950\">A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00337207\">Bevacizumab in Treating Patients With Recurrent or Progressive Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00268359\">Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00795665\">Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01164189\">Bevacizumab in Recurrent Grade II and III Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00352521\">Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT01183663\">Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)<\/a>","<a href=\"https://ClinicalTrials.gov/show/NCT00782756\">Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma<\/a>"],["Active, not recruiting","Completed","Recruiting","Completed","Recruiting","Terminated","Completed","Recruiting","Completed","Recruiting","Recruiting","Completed","Completed","Withdrawn","Unknown status","Completed","Active, not recruiting","Completed","Completed","Terminated","Completed","Completed","Suspended","Completed","Completed","Completed","Active, not recruiting","Recruiting","Completed","Completed","Completed","Completed","Completed","Completed","Active, not recruiting","Completed","Completed","Completed","Completed","Completed","Withdrawn","Terminated","Completed","Completed","Withdrawn","Withdrawn","Recruiting","Completed","Completed","Not yet recruiting","Completed","Completed","Withdrawn","Active, not recruiting","Active, not recruiting","Active, not recruiting","Completed","Completed","Active, not recruiting","Completed","Withdrawn","Completed","Completed","Recruiting","Completed","Completed","Terminated","Terminated","Terminated","Active, not recruiting","Active, not recruiting","Completed","Active, not recruiting","Completed","Recruiting","Active, not recruiting","Completed","Terminated","Completed","Completed","Completed","Suspended","Withdrawn","Recruiting","Completed","Completed","Active, not recruiting","Terminated","Recruiting","Completed","Completed","Completed","Recruiting","Completed","Unknown status","Completed","Terminated","Completed","Completed","Completed","Completed","Terminated","Recruiting","Completed","Active, not recruiting","Unknown status","Completed","Terminated","Recruiting","Active, not recruiting","Completed","Completed","Withdrawn","Completed","Completed","Terminated","Completed","Completed","Terminated","Completed","Terminated","Recruiting","Completed","Recruiting","Completed","Recruiting","Completed","Completed","Completed","Completed","Completed","Completed","Completed"],["Drug: Pembrolizumab|Drug: Bevacizumab|Radiation: Re-irradiation","Device: FMISO PET|Device: MRI|Drug: Bevacizumab|Drug: CCNU","Drug: Camrelizumab and Bevacizumab","Drug: VB-111 + bevacizumab|Drug: Bevacizumab","Drug: Olaptesed pegol|Radiation: Radiotherapy|Drug: Bevacizumab","Drug: F-MISO|Other: Cerebral magnetic resonance imagery|Drug: Bevacizumab|Other: Clinical examination","Drug: Temozolomide|Drug: Bevacizumab|Radiation: Standard radiation therapy","Radiation: Re-irradiation (RT)|Drug: Bevacizumab|Drug: Nivolumab|Procedure: Re-resection","Drug: Bevacizumab 25 mg in 1 ml subcutaneously daily","Drug: Selinexor|Drug: Temozolomide (TMZ)|Drug: Lomustine (CCNU)|Radiation: Standard Fractionated Radiation therapy (RT)|Drug: Bevacizumab|Device: TTField|Drug: Carmustine","Drug: DSP-7888 Dosing Emulsion|Drug: Bevacizumab","Drug: Bevacizumab|Drug: Temozolomide|Radiation: RT (Radiation Therapy)","Drug: Durvalumab|Radiation: Standard radiotherapy|Biological: Bevacizumab","Drug: Cilengitide|Drug: Bevacizumab|Behavioral: Questionnaire","Drug: Monoclonal antibody|Drug: Bevacizumab|Biological: Blood sample|Device: Dynamic Contrast Enhanced magnetic resonance imaging (DCE-MRI)","Drug: Amgen 386|Drug: Bevacizumab","Drug: Capecitabine|Drug: Bevacizumab","Drug: Bevacizumab|Drug: TH-302","Drug: bevacizumab and Irinotecan and radiotherapy|Drug: Bevacizumab and Temozolomide and radiotherapy","Drug: TPI 287|Drug: Bevacizumab","Drug: Vorinostat|Drug: Bevacizumab|Drug: Irinotecan","Drug: Bevacizumab|Radiation: Radiation therapy","Drug: TPI 287|Drug: Bevacizumab","Drug: Bevacizumab|Procedure: Magnetic Resonance Spectroscopy (MRS)|Procedure: Border Zone Stereotactic Radiosurgery (BZ-SRS)","Drug: bevacizumab|Drug: irinotecan","Drug: Bevacizumab|Drug: BKM120","Biological: Bevacizumab|Drug: Cediranib|Drug: Cediranib Maleate|Drug: Olaparib","Drug: Bevacizumab","Drug: Bevacizumab|Drug: Onartuzumab|Drug: Placebo","Drug: Bevacizumab|Drug: Lomustine|Drug: Placebo|Radiation: Radiotherapy|Drug: Temozolomide|Drug: SOC Agent","Biological: bevacizumab|Drug: dasatinib|Other: placebo","Drug: TRC105|Drug: Bevacizumab","Drug: bevacizumab [Avastin]|Drug: fotemustine","Drug: Temozolomide, bevacizumab and bortezomib","Biological: Nivolumab|Biological: Bevacizumab|Biological: Ipilimumab","Drug: Bevacizumab|Drug: Temozolomide|Radiation: Radiation therapy|Drug: Placebo","Drug: RO5323441 + bevacizumab [Avastin]|Drug: bevacizumab [Avastin]","Drug: bevacizumab [Avastin]|Drug: temozolomide","Drug: Temsirolimus|Drug: Bevacizumab","Drug: Bevacizumab","Drug: BCNU Wafer|Drug: Irinotecan|Drug: Bevacizumab","Biological: [18F]fluoromisonidazole|Drug: Bevacizumab|Radiation: positron emission tomography (PET/CT).","Drug: Bevacizumab and Temozolomide","Biological: SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)|Drug: Bevacizumab","Drug: Tandutinib, bevacizumab, and temozolomide","Drug: Fluciclitite , PET imaging, and Bevacizumab","Drug: VB11|Procedure: Surgery|Other: Placebo|Drug: Bevacizumab","Drug: vorinostat|Drug: bevacizumab","Drug: Bevacizumab|Behavioral: Modified Atkins Diet","Drug: ASC40 tablets|Drug: Placebo tablets|Drug: Bevacizumab","Drug: Temozolomide|Drug: Bevacizumab","Drug: VB-111|Drug: Bevacizumab","Drug: Bevacizumab|Biological: Peptide Vaccine|Drug: Poly-ICLC as immune adjuvant|Drug: Keyhole limpet hemocyanin (KLH)","Drug: ABI-009|Drug: Bevacizumab|Drug: Temozolomide|Drug: Lomustine|Radiation: Radiation|Drug: Marizomib","Biological: bevacizumab|Drug: temozolomide|Other: laboratory biomarker analysis|Other: immunohistochemistry staining method|Genetic: microarray analysis|Genetic: DNA methylation analysis","Drug: ERC1671|Drug: GM-CSF|Drug: Cyclophosphamide|Drug: Oral Control (Sucrose pill)|Drug: Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%))|Drug: Bevacizumab/Bevacizumab Biosimilar","Drug: Standard Dose Bevacizumab|Drug: Low Dose Bevacizumab|Drug: Lomustine","Drug: Bevacizumab|Drug: Tarceva|Drug: Temozolomide","Drug: Nivolumab|Drug: Standard Dose Bevacizumab|Drug: Low Dose Bevacizumab","Drug: Pembrolizumab|Drug: Bevacizumab","Drug: Bevacizumab (Avastin)","Drug: temozolomide and bevacizumab","Radiation: Radiation therapy|Drug: Temozolomide|Drug: Bevacizumab|Drug: Everolimus","Drug: Temozolomide|Drug: Bevacizumab","Drug: bevacizumab [Avastin]|Drug: irinotecan|Drug: temozolomide","Radiation: 3-Dimensional Conformal Radiation Therapy|Biological: Bevacizumab|Radiation: Intensity-Modulated Radiation Therapy|Other: Laboratory Biomarker Analysis|Other: Placebo|Other: Quality-of-Life Assessment|Drug: Temozolomide","Radiation: radiosurgery|Biological: bevacizumab|Drug: irinotecan hydrochloride","Drug: Bevacizumab|Device: TTFields Therapy","Drug: Bevacizumab|Device: Optune|Other: Brain MRI|Other: Quality of Life Questionnaires","Biological: HSPPC-96|Drug: bevacizumab","Biological: bevacizumab|Radiation: radiation therapy","Biological: Bevacizumab|Device: NovoTTF-l00A|Other: Quality of Life Assessment","Drug: Bevacizumab|Drug: Temozolomide|Radiation: Radiation Therapy (XRT)|Drug: Topotecan","Drug: Bevacizumab/Irinotecan","Drug: Abemaciclib|Drug: Bevacizumab","Drug: Bevacizumab","Biological: Bevacizumab|Drug: Irinotecan Hydrochloride|Drug: Temozolomide","Biological: ALECSAT|Drug: Bevacizumab/Irinotecan","Drug: Bevacizumab|Drug: Nimustine","Biological: Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy|Biological: Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab","Drug: Bevacizumab standard of care","Drug: Bevacizumab and Carboplatin","Procedure: Electric Field Therapy|Biological: Bevacizumab|Drug: Carmustine|Other: Quality-of-Life Assessment","Drug: Bevacizumab","Drug: Bevacizumab|Drug: Rindopepimut (CDX-110) with GM-CSF|Drug: KLH","Drug: Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB","Drug: INC280|Biological: bevacizumab","Biological: Toca 511|Drug: Toca FC|Drug: Lomustine|Drug: Temozolomide|Biological: Bevacizumab","Radiation: Radiation: Intra-operative Radiation Therapy - IORT|Drug: Bevacizumab|Drug: Avastin","Drug: Cetuximab|Drug: Bevacizumab|Drug: Irinotecan","Drug: Bevacizumab|Drug: Metronomic Temozolomide","Biological: bevacizumab|Drug: lomustine|Genetic: DNA methylation analysis|Other: laboratory biomarker analysis|Procedure: cognitive assessment|Procedure: quality-of-life assessment","Drug: Nivolumab|Drug: Bevacizumab","Drug: enzastaurin|Drug: bevacizumab|Drug: Enzyme-inducing antiepileptic drugs (EIAED)|Drug: Non-enzyme inducing antiepileptic drugs (NEIAED)","Drug: Neuradiab in combination with Bevacizumab (Avastin)","Biological: bevacizumab|Drug: sorafenib tosylate","Device: NovoTTF100A|Drug: Bevacizumab|Drug: Temozolomide","Drug: bevacizumab|Drug: erlotinib hydrochloride","Biological: bevacizumab|Drug: temozolomide|Radiation: external beam radiation therapy","Drug: Bevacizumab and Etoposide","Biological: Anti-Endoglin Chimeric Monoclonal Antibody TRC105|Biological: Bevacizumab|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Other: Quality-of-Life Assessment","Dietary Supplement: Ascorbic Acid|Biological: Bevacizumab|Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment","Drug: Epacadostat|Drug: Bevacizumab|Radiation: Radiation therapy|Procedure: Peripheral blood draw","Drug: Vorinostst/Bevacizumab/Temozolomide","Biological: Bevacizumab|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Sapanisertib","Drug: Cannabidiol|Drug: Bortezomib|Drug: Leucovorin|Drug: 5-FU|Drug: Oxaliplatin|Drug: Bevacizumab|Drug: Irinotecan|Drug: Gemcitabine|Drug: Temozolomide","Drug: Bevacizumab and Erlotinib","Drug: TPI287|Drug: Bevacizumab","Device: NaviFUS System|Drug: Bevacizumab","Biological: Bevacizumab|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Other: Placebo Administration|Biological: Trebananib","Drug: ANG1005|Drug: Bevacizumab","Drug: Vorinostat|Drug: Bevacizumab","Drug: Crizotinib plus VEGF inhibitor combinations|Drug: Crizotinib plus axitinib|Drug: Crizotinib plus sunitinib|Drug: Crizotinib plus bevacizumab|Drug: Crizotinib plus sorafenib","Radiation: Radiation Therapy|Drug: Temozolomide|Drug: Bevacizumab","Drug: Indoximod|Drug: Temozolomide|Drug: Bevacizumab|Radiation: Stereotactic Radiation","Drug: Temozolomide|Radiation: hypofractionated radiation therapy|Biological: bevacizumab|Other: questionnaire administration","Biological: Bevacizumab|Drug: MLN-518 (Tandutinib)|Procedure: Quality-of-life assessment","Biological: bevacizumab|Drug: cediranib maleate","Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097|Biological: bevacizumab|Other: laboratory biomarker analysis|Other: pharmacological study","Drug: Irinotecan|Drug: Bevacizumab|Device: FDOPA-PET/MRI imaging","Drug: Plerixafor|Drug: Bevacizumab|Procedure: Surgery","Drug: Mebendazole|Drug: Vincristine|Drug: Carboplatin|Drug: Temozolomide|Drug: Bevacizumab|Drug: Irinotecan","Other: Bevacizumab & Stereotactic Radiotherapy","Drug: SIACI of Erbitux and Bevacizumab","Drug: Valproic acid|Drug: Bevacizumab|Radiation: Radiation therapy","Drug: Bevacizumab|Radiation: PRDR","Biological: bevacizumab","Biological: bevacizumab|Drug: irinotecan hydrochloride","Drug: bevacizumab|Drug: carmustine","Biological: Bevacizumab|Drug: Temozolomide","Drug: bevacizumab|Drug: irinotecan|Procedure: dynamic contrast-enhanced magnetic resonance imaging","Drug: Lenalidomide|Drug: Bevacizumab|Drug: Sorafenib|Drug: Temsirolimus|Drug: Oxaliplatin|Drug: Leucovorin|Drug: 5-fluorouracil","Other: radiotherapy (RT) in combination with temozolomide and bevacizumab"],["Phase 2","Not Applicable","Phase 2","Phase 3","Phase 1|Phase 2","Not Applicable","Phase 2","Phase 2","Phase 2","Phase 1|Phase 2","Phase 3","Phase 2","Phase 2","Phase 2","Phase 1","Phase 1|Phase 2","Phase 1","Phase 2","Phase 2","Phase 2","Phase 1","Phase 2","Phase 1|Phase 2","Phase 2","Phase 2","Phase 1|Phase 2","Phase 2","Phase 1","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 1","Phase 3","Phase 3","Phase 1","Phase 2","Phase 2","Early Phase 1","Phase 1|Phase 2","Phase 1","Phase 2","Phase 1|Phase 2","Phase 1","Phase 2","Phase 2","Phase 1|Phase 2","Early Phase 1","Phase 3","Phase 2","Phase 1|Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Early Phase 1","Phase 2","Phase 2","Phase 3","Phase 2","Phase 3","Early Phase 1","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Early Phase 1","Phase 1|Phase 2","Phase 2","Phase 2","Phase 2","Phase 1","Not Applicable","Phase 1|Phase 2","Phase 2","Phase 1|Phase 2","Phase 2","Phase 1","Phase 1","Phase 2|Phase 3","Phase 2","Phase 2","Phase 2","Phase 3","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 1|Phase 2","Phase 1","Phase 2","Phase 1|Phase 2","Phase 1","Phase 1|Phase 2","Phase 2","Phase 1|Phase 2","Not Applicable","Phase 2","Phase 2","Phase 2","Phase 1","Phase 2","Phase 1|Phase 2","Phase 2","Phase 2","Phase 1","Phase 1|Phase 2","Phase 1","Phase 1","Phase 1|Phase 2","Phase 1","Phase 1|Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 1","Phase 2"],["7-Sep-18","3-Mar-14","7-Jul-21","30-Jul-15","10-Oct-19","22-Jul-16","13-Apr-10","16-Nov-18","5-Jun-14","9-Jun-20","11-May-17","27-Sep-10","12-Jan-15","4-Feb-13","15-Aug-18","4-Feb-11","1-Feb-16","19-Jan-15","6-Jan-09","28-Jan-14","30-Sep-08","30-Sep-11","2-Sep-13","22-Apr-14","27-Jun-06","6-May-11","28-Nov-16","7-Nov-14","2-Jul-12","23-May-13","4-May-09","28-Mar-12","18-Nov-11","16-Sep-11","23-Dec-13","22-Jul-09","4-Mar-11","4-May-10","2-Dec-08","24-Mar-10","25-Sep-09","29-Jun-18","11-Jan-08","5-Mar-14","20-May-09","11-Feb-13","28-May-20","24-Dec-10","11-May-16","12-Nov-21","13-Sep-16","15-Dec-10","28-Apr-16","13-Mar-18","24-Jun-10","19-Jul-13","11-Feb-10","5-Sep-07","2-Mar-18","13-Jan-15","8-Apr-11","17-Apr-09","10-Dec-08","4-May-16","27-Aug-09","21-Apr-09","15-Mar-10","19-Apr-16","26-Jan-16","20-Mar-13","21-Nov-12","9-Jul-13","30-Oct-09","16-Jun-09","30-Aug-19","14-Mar-13","12-Feb-07","12-Feb-14","3-Mar-16","13-Dec-13","22-Apr-13","1-Jul-11","28-Jan-15","4-Jan-11","23-Dec-11","28-Aug-09","12-Mar-15","10-Apr-15","23-Dec-20","20-Apr-07","16-Jul-07","7-Feb-11","26-Mar-19","4-Jan-08","21-May-09","22-Feb-08","22-Jan-15","22-Jul-08","13-Nov-09","11-Feb-08","24-Jul-12","14-Jul-16","22-May-18","15-Jul-09","20-May-14","31-Jul-18","6-May-08","20-Apr-12","24-Jun-20","1-Jun-12","23-Oct-13","30-Nov-12","27-Sep-11","4-Dec-12","3-Feb-14","23-Nov-11","28-Apr-08","11-Apr-07","26-Aug-10","3-Dec-13","20-Apr-11","23-Apr-13","12-Jul-11","24-Jun-13","10-Apr-09","6-Dec-12","15-Jun-06","22-Dec-05","21-Nov-08","16-Jul-10","14-Jul-06","17-Aug-10","31-Oct-08"]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>NCT.Number<\/th>\n      <th>Title<\/th>\n      <th>Status<\/th>\n      <th>Interventions<\/th>\n      <th>Phases<\/th>\n      <th>First.Posted<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"dom":"p","pageLength":5,"order":[],"autoWidth":false,"orderClasses":false,"columnDefs":[{"orderable":false,"targets":0}],"lengthMenu":[5,10,25,50,100]}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="network-plots" class="section level3">
<h3>Network Plots</h3>
<pre><code>No id variables; using all as measure variables</code></pre>
<pre><code>Using X as id variables</code></pre>
<pre><code>Using Gene_ID as id variables</code></pre>
<pre><code>`stat_bin()` using `bins = 30`. Pick better value with `binwidth`.</code></pre>
<p><img src="figure/TT.Rmd/unnamed-chunk-1-1.png" width="672" style="display: block; margin: auto;" /></p>
<hr />
<br>
<p>
<button type="button" class="btn btn-default btn-workflowr btn-workflowr-sessioninfo" data-toggle="collapse" data-target="#workflowr-sessioninfo" style="display: block;">
<span class="glyphicon glyphicon-wrench" aria-hidden="true"></span> Session information
</button>
</p>
<div id="workflowr-sessioninfo" class="collapse">
<pre class="r"><code>sessionInfo()</code></pre>
<pre><code>R version 4.0.5 (2021-03-31)
Platform: x86_64-apple-darwin17.0 (64-bit)
Running under: macOS Catalina 10.15.7

Matrix products: default
BLAS:   /Library/Frameworks/R.framework/Versions/4.0/Resources/lib/libRblas.dylib
LAPACK: /Library/Frameworks/R.framework/Versions/4.0/Resources/lib/libRlapack.dylib

locale:
[1] en_US.UTF-8/en_US.UTF-8/en_US.UTF-8/C/en_US.UTF-8/en_US.UTF-8

attached base packages:
[1] parallel  stats4    stats     graphics  grDevices utils     datasets 
[8] methods   base     

other attached packages:
 [1] reshape2_1.4.4         fs_1.5.0               tictoc_1.0.1          
 [4] data.table_1.14.0      org.Hs.eg.db_3.12.0    AnnotationDbi_1.52.0  
 [7] IRanges_2.24.1         S4Vectors_0.28.1       Biobase_2.50.0        
[10] BiocGenerics_0.36.1    ReactomePA_1.34.0      enrichplot_1.10.2     
[13] msigdbr_7.2.1          clusterProfiler_3.18.1 plyr_1.8.6            
[16] jsonlite_1.7.2         gridExtra_2.3          DT_0.19               
[19] here_1.0.1             forcats_0.5.1          stringr_1.4.0         
[22] dplyr_1.0.5            purrr_0.3.4            readr_1.4.0           
[25] tidyr_1.1.3            tibble_3.1.0           ggplot2_3.3.5         
[28] tidyverse_1.3.1       

loaded via a namespace (and not attached):
  [1] readxl_1.3.1        shadowtext_0.0.7    backports_1.2.1    
  [4] fastmatch_1.1-0     workflowr_1.6.2     igraph_1.2.6       
  [7] splines_4.0.5       BiocParallel_1.24.1 crosstalk_1.1.1    
 [10] digest_0.6.27       htmltools_0.5.1.1   GOSemSim_2.16.1    
 [13] viridis_0.6.0       GO.db_3.12.1        fansi_0.4.2        
 [16] magrittr_2.0.1      checkmate_2.0.0     memoise_2.0.0      
 [19] graphlayouts_0.7.1  modelr_0.1.8        colorspace_2.0-0   
 [22] blob_1.2.1          rvest_1.0.0         rappdirs_0.3.3     
 [25] ggrepel_0.9.1       haven_2.4.0         xfun_0.22          
 [28] crayon_1.4.1        graph_1.68.0        scatterpie_0.1.5   
 [31] glue_1.4.2          polyclip_1.10-0     gtable_0.3.0       
 [34] graphite_1.36.0     scales_1.1.1        DOSE_3.16.0        
 [37] DBI_1.1.1           Rcpp_1.0.6          viridisLite_0.4.0  
 [40] xtable_1.8-4        bit_4.0.4           reactome.db_1.74.0 
 [43] htmlwidgets_1.5.3   httr_1.4.2          fgsea_1.16.0       
 [46] RColorBrewer_1.1-2  ellipsis_0.3.1      pkgconfig_2.0.3    
 [49] farver_2.1.0        sass_0.3.1          dbplyr_2.1.1       
 [52] utf8_1.2.1          tidyselect_1.1.0    labeling_0.4.2     
 [55] rlang_0.4.10        later_1.1.0.1       munsell_0.5.0      
 [58] cellranger_1.1.0    tools_4.0.5         cachem_1.0.4       
 [61] downloader_0.4      cli_3.0.1           generics_0.1.0     
 [64] RSQLite_2.2.5       broom_0.7.6         evaluate_0.14      
 [67] fastmap_1.1.0       yaml_2.2.1          knitr_1.32         
 [70] bit64_4.0.5         tidygraph_1.2.0     ggraph_2.0.5       
 [73] mime_0.10           DO.db_2.9           xml2_1.3.2         
 [76] compiler_4.0.5      rstudioapi_0.13     reprex_2.0.0       
 [79] tweenr_1.0.2        bslib_0.2.4         stringi_1.5.3      
 [82] highr_0.9           lattice_0.20-41     Matrix_1.3-2       
 [85] vctrs_0.3.7         pillar_1.6.0        lifecycle_1.0.0    
 [88] BiocManager_1.30.12 jquerylib_0.1.3     cowplot_1.1.1      
 [91] httpuv_1.5.5        qvalue_2.22.0       R6_2.5.0           
 [94] promises_1.2.0.1    MASS_7.3-53.1       assertthat_0.2.1   
 [97] rprojroot_2.0.2     withr_2.4.2         hms_1.0.0          
[100] grid_4.0.5          rmarkdown_2.7       rvcheck_0.1.8      
[103] git2r_0.28.0        ggforce_0.3.3       shiny_1.6.0        
[106] lubridate_1.7.10   </code></pre>
</div>
</div>
</div>


<!-- Adjust MathJax settings so that all math formulae are shown using
TeX fonts only; see
http://docs.mathjax.org/en/latest/configuration.html.  This will make
the presentation more consistent at the cost of the webpage sometimes
taking slightly longer to load. Note that this only works because the
footer is added to webpages before the MathJax javascript. -->
<script type="text/x-mathjax-config">
  MathJax.Hub.Config({
    "HTML-CSS": { availableFonts: ["TeX"] }
  });
</script>





</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
